cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5255/ukda-sn-7614-1
title: Employer Perspectives Survey, 2014
title: Employer Perspectives Surveys, 2007-
title: UKCEPS

description: The &lt;i&gt;Employer Perspectives Survey&lt;/i&gt; (EPS) is a large scale survey of UK employers across all sectors of the economy and is part of a series of studies historically commissioned by the UK Commission for Employment and Skills (UKCES) to provide robust and reliable labour market information. Following the closure of the UKCES ownership of the survey transferred to the Department for Education (DfE) in late 2016.&lt;br&gt;
&lt;br&gt;
The survey provides a UK-wide picture of how employers are meeting their skills needs, looking both at their engagement with skills and employment services and broader approaches to people development. The &lt;i&gt;Employer Perspectives Survey&lt;/i&gt; is a key customer insight tool for colleges, universities, schools and other providers looking to understand how employers view and engage with the skills system.&lt;br&gt;
&lt;br&gt;
The &lt;i&gt;Employer Perspectives Survey&lt;/i&gt; is intended to complement the &lt;i&gt;Employer Skills Survey&lt;/i&gt; series, which focuses on employer skills demand, skills shortages and training within organisations; the two surveys run in alternate years.&lt;br&gt;
&lt;br&gt;
 The &lt;i&gt;Employer Perspectives Survey, 2014&lt;/i&gt; covered over 18,000 employers across the full geographical spread of the UK, in all sectors of the economy (across the commercial, public and charitable spheres). The survey examined: approaches to recruitment; awareness and use of skills support services/initiatives; engagement with external training providers, and the use of vocational qualifications and apprenticeships.&lt;br&gt;
&lt;br&gt;
DOI: 10.5255/ukda-sn-7615-2
title: Understanding Society: Interviewer Survey, 2014
title: USIS; UKHLS

description: The &lt;i&gt;Understanding Society: Interviewer Survey 2014&lt;/i&gt; data file is the output of a research project that collected information from interviewers who worked on the Understanding Society data collection for Great Britain in the first round of interviews, which took place over the course of the years 2009 and 2010. &lt;br&gt; &lt;br&gt; One of the specific aims of the data collection was to better understand the nature of bias in respondent consent to data linkage and, in particular, the role of interviewers in obtaining consent and in affecting consent bias. Hence, the interviewer survey includes a number of questions eliciting interviewer attitudes to consent to data linkage and their experiences with asking for consent during the fieldwork. There are, however, also a great deal of questions that will be of interest to a greater audience of researchers, such as interviewer attitudes to persuasion, measures of their personality traits and markers of general trust.&lt;br&gt; &lt;br&gt;
DOI: 10.15468/dl.dgav3s
title: Occurrence Download

description: A dataset containing 3561 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Arkansas Plecoptera V1 data set"
 ]
}

 The dataset includes 3561 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0004858-250415084134356/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6073/pasta/057404728eb931f41455c5c5c5ca6652
title: Dissolved organic carbon (DOC) in Imnavait Creek, Foothills, Brooks Range, Alaska, 2002-2009.

description: This file contains data on dissolved organic carbon concentrations from the main weir at Imnavait Creek on the North Slope of Alaska. The data coverage is from 2002 to 2009. Concentrations are expressed in micromoles of carbon per liter of water.
DOI: 10.6084/m9.figshare.27019747
title: Supplementary Material for: Effective management of chronic intestinal pseudo-obstruction in MELAS using acotiamide: A case report

description: Background: Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is reported to be a secondary cause of chronic intestinal pseudo-obstruction (CIPO). Although few case reports have described CIPO in MELAS, effective treatment for CIPO has not been established. Here, we present a case report of amelioration of CIPO symptoms using acotiamide in a patient with MELAS.
Case Presentation: A 51-year-old Japanese female with a mitochondrial disorder with m.3243A&gt;G mutation and a history of anorexia for two years presented to our hospital with a left temporal headache and acute paraphasia. A stroke-like episode of MELAS was suspected, and combined therapy with arginine, edaravone, and levetiracetam was initiated. Although her symptoms improved, she presented with nausea and vomiting and abdominal distension six days following admission. Abdominal contrast-enhanced computed tomography revealed dilatation from the stomach to the intestine, particularly marked the stomach, with neither obstruction nor impaired blood flow in the intestine. CIPO exacerbation with MELAS was suspected, and the patient’s symptoms gradually improved with acotiamide.
Conclusion: Patients with MELAS could possibly experience stroke-like episodes during CIPO. Since acetylcholine possibly plays an important role in the pathophysiology of CIPO and acotiamide possesses prokinetic activity by inhibiting acetylcholinesterase, acotiamide could possibly improve CIPO symptoms.
DOI: 10.6084/m9.figshare.27282645
title: Supplementary Material for: Analysis of chromosome test results of 24,175 miscarried fetuses in Japan from 2000 to 2021

description: Background : Fetal chromosome abnormalities, the most common cause of spontaneous abortion, were investigated pre-1980s. In recent years, chromosome testing has been outsourced to testing companies in Japan, and there have been few epidemiological studies of chromosome testing of miscarried fetuses on a nationwide scale. 
Methods : We analyzed the chromosome test data of SRL, Inc., one of the largest clinical laboratories that has collected tissue specimens of products of conception derived from miscarried fetuses from hospitals throughout Japan from 2000. 
Results : We collected and analyzed 24,175 cases, among which 8,726 (36.1%) were normal chromosomes, 1,298 (5.4%) were sex chromosome abnormalities, 9,735 (40.3%) were autosomal trisomies, 73 (0.3%) were autosomal monosomies, 840 (3.5%) were ploidy, 512 (2.1%) were chromosome structural abnormalities, and 2,991 (12.4%) were mosaics. The frequency of autosomal trisomy increased at the older maternal ages. By chromosome number, trisomies 22, 16, 21, and 15 were associated with advanced maternal age, but trisomies 13, 14, and 18 were not associated with advanced maternal age. The presence or absence of this maternal age effect was correlated with the chromosome segregation being due to maternal meiosis I or meiosis II. For the sex ratios of the fetuses, we focused on trisomies 22, 21, 18, 16, 15, 14, and 13, and found that only trisomy 16 was significantly more frequently seen in female fetuses. 
Conclusion : The findings of this study provide insights into the basic understanding of miscarriage and will be useful in counseling and medical education.
DOI: 10.6084/m9.figshare.27283461
title: Supplementary Material for: Early Screening and Identification of an Asymptomatic Pheochromocytoma in a child with Von-Hippel Lindau: a case report

description: Von Hippel-lindau (VHL) is a diagnosis that leads to increased risk of tumor development over the course of the patient’s lifetime. Patients with VHL undergo screening for multiple tumor types, including pheochromocytomas (PCC). There is not consensus among the different international guidelines regarding the age to begin PCC screening in VHL patients, though most recommend screening beginning at age 5 years. Here we present a case of an asymptomatic PCC identified in a 4-year-old on screening labs that was treated with laparoscopic partial adrenalectomy, supporting consideration for earlier initiation of screening in pediatric VHL patients.
DOI: 10.6084/m9.figshare.27713913
title: Supplementary Material for: Efficacy and safety of transdermal medical cannabis (THC:CBD: CBN formula) to treat painful diabetic peripheral neuropathy of the lower extremities

description: Abstract
Introduction: Diabetic peripheral neuropathy (DPN) represents a prevalent neurological complication affecting millions of patients globally. This clinical investigation evaluated the therapeutic efficacy and safety profile of a novel transdermal medical cannabis formulation (THC:CBD:CBN) in treating painful DPN of the lower extremities.
Methods: This phase III, double-blind, placebo-controlled, randomized clinical trial was conducted at Don Chan Hospital, Thailand, enrolling 100 participants over a 12-week intervention period. Using a computer-generated randomization sequence, participants were allocated to receive either the standardized cannabis formulation or a matched placebo. The primary outcome measure comprised pain intensity assessment using the validated Thai version of the Neuropathic Pain Symptom Inventory (NPSI-T). Secondary outcomes encompassed treatment-emergent adverse events and dermatological manifestations. Statistical analyses were performed using SPSS Version 28.0, incorporating Generalized Estimating Equation (GEE) modeling and Analysis of Covariance (ANCOVA). The study protocol received approval from the Institutional Review Board of Khon Kaen University and the Kalasin Provincial Public Health Office Ethics Committee, with trial registration in the Thai Clinical Trials Registry.
Results: The intervention group demonstrated statistically significant reductions in NPSI-T scores across all measured dimensions (p&lt;0.001). Mean total NPSI-T scores decreased markedly from 25.60 to 5.57 in the treatment cohort, contrasting with minimal reduction from 25.24 to 22.85 in the placebo group. GEE analysis revealed significant pain amelioration at weeks 4, 8, and 12 (p&lt;0.001). The cannabis formulation exhibited an excellent safety profile, with only 10% of participants reporting mild adverse events, comparable to placebo group outcomes.
Conclusion: This novel transdermal medical cannabis formulation (THC:CBD:CBN) demonstrated significant therapeutic efficacy in ameliorating painful DPN symptoms while maintaining a favorable safety profile. These findings provide robust clinical evidence supporting its potential as an innovative therapeutic option for managing painful diabetic peripheral neuropathy.
DOI: 10.6084/m9.figshare.27717489
title: Supplementary Material for: Behind Bars: Exploring Health and Geriatric Conditions Among Incarcerated Older People in Mexican prisons.

description: Introduction
The aging process of the incarcerated population is a growing concern, yet there are few data on older adults in this demographic group. Hence, this study seeks to examine the health status of older adults who are incarcerated in Mexican prisons and its association with the duration of their imprisonment.

Methods
This is a secondary analysis of the 2021 Mexico National Prisons Survey. We analyzed 50-year-old and older prisoners, and performed a descriptive analysis of the sample’s age, sex, sociodemographic variables, and chronic conditions. Multivariate analysis stratified by age was performed to assess the effect of the time spent in prison on older prisoners’ health.

Results
The mean age was 56.95 (± 6.4 SD) and the mean duration of imprisonment was 8.93 years (± 6.94 SD). Regarding health conditions, 17.80% had diabetes, 29.62% had hypertension, 10.33% had suicidal ideation, 40.87% were visually impaired, 17.01% had hearing impairment, and 17.64% had mobility impairment. Multivariate analysis revealed that among categories of imprisonment duration, longer time imprisoned was associated with an increased risk of diabetes and hypertension for all groups but was not associated with mobility impairment or suicidal ideation except in the younger group. 

Conclusion
Longer periods of incarceration appear to be associated with a greater occurrence of diabetes and hypertension in older prisoners. Sensory impairments and suicidal ideation are mainly identified in younger prisoners, while mobility impairments do not appear to be influenced by the time spent in prison. Further research needs to be done in prisons, where the addition of physical performance tests and cognitive tests could help further study geriatric conditions in older prisoners.
DOI: 10.6084/m9.figshare.27722037
title: Supplementary Material for: The Care of Preterm and Term Newborns with Respiratory Conditions: A Systematic Synthesis of Evidence from Low- and Middle-Income Countries

description: Introduction: Neonatal respiratory conditions are leading causes of mortality and morbidity during the neonatal period. This review evaluated 11 management interventions for respiratory distress syndrome (RDS), apnoea of prematurity (AOP), meconium aspiration syndrome (MAS), transient tachypnea of the newborn (TTN), as well as bronchopulmonary dysplasia (BPD) as a potential complication from respiratory care in low- and middle-income countries (LMICs).

Methods: Two different methodological approaches were completed: (1) updating outdated reviews and pooling all LMIC studies and (2) re-analysis of LMIC studies from up-to-date reviews. Review updates were conducted between October 2022 and February 2023 and followed systematic methodology. A total of 50 studies were included across four review updates and seven review re-analyses. 

Results: Findings indicate that bubble CPAP (RR 0.74, 95% CI 0.58 to 0.96) and prophylactic CPAP (RR 0.39, 95% CI 0.26 to 0.57) for RDS reduced the risk of treatment failure compared to other ventilation types or supportive care, respectively. Postnatal corticosteroids reduced BPD assessed as oxygen requirement at 36 weeks’ postmenstrual age (RR 0.56, 95% CI 0.41 to 0.77). All other outcomes were found to be non-significant across remaining interventions.

Conclusions: Our findings indicate that prophylactic and bubble CPAP may provide some benefit by reducing treatment failure compared to other pressure sources. The safety and efficacy of other management interventions for RDS, AOP, BPD, MAS, and TTN remains uncertain given limited evaluations in LMICs. Future research should conduct adequately powered trials in underrepresented LMIC regions, investigate long-term outcomes, and evaluate cost-effectiveness.
DOI: 10.6084/m9.figshare.27751227
title: Supplementary Material for: Palbociclib in combination with either aromatase inhibitors or fulvestrant for patients with advanced HR+/HER2- breast cancer in Germany - Final results of the phase 2 multicohort INGE-B trial

description: Introduction 
The INGE-B trial (NCT02894398) aimed to confirm the efficacy and safety data from the PALOMA trials for patients treated first line (1L) with palbociclib (PAL) and letrozole or 1L and later line with PAL and fulvestrant. In addition, efficacy and safety on the combination of PAL with anastrozole, exemestane (1L), or letrozole (later line) was investigated.
Methods 
The prospective, multicenter, multi-cohort phase 2 trial INGE-B enrolled adult patients with locally advanced, inoperable, or metastatic HR+/HER2- breast cancer in Germany. The primary endpoint was the clinical benefit rate (CBR) in patients with measurable disease according to RECIST v1.1. Secondary endpoints were overall response rate (ORR), progression free survival (PFS), overall survival (OS), safety and quality of life. Data were analyzed with descriptive statistics. 
Results 
Between 2016 and 2018, 388 patients were enrolled at 64 German sites. Among patients with measurable disease treated with PAL in 1L (n=157), the CBR was 63.7% (100/157). Among all patients treated with PAL 1L (n=219), PFS was 20.1 months (95% CI 14.6 – 24.0) and OS was 40.9 months (95% CI 35.1-49.2). The most common grade 3/4 adverse event was neutropenia (33.4% n=77). There were no treatment-related deaths.
Conclusion 
The INGE-B trial demonstrated good efficacy and tolerability of PAL with letrozole (1L) or fulvestrant (first and later line) in accordance with the PALOMA-trials. In addition, the so far lacking proof of efficacy and safety of PAL in combination with anastrozole or exemestane in 1L and with letrozole in later line was provided by INGE-B.
DOI: 10.18739/a24746t0k
title: Snow depth survey in North Slope, Alaska, 2022

description: This is the field measured snow depth data using an automatic snow depth probe (magnaprobe, Snow-Hydro LCC) in April 19 - May 7, 2022 in North Slope, Alaska. The data are in csv format (comma delimited text format with geographical coordinate, WGS 84, and UTM zone 5). The goal of this research project is to quantify the role of thermokarst lake drainage and drained thermokarst lake basin (DTLB) evolution in the arctic system. The joint research team (University of Alaska, Fairbanks, University of Wyoming, and Michigan Technological University) spent several days based in Utqiagvik (Western Coastal Plain) and rest of days in Teshekpuk Lake (Central Coastal Plain). During the travel, manual snow survey was conducted using the mangaprobe to quantify the snowdrift around thermokarst lakes and other land features as complementary to the geophysical and remote sensed snowpack characterizations.
DOI: 10.24432/c5rs3s
title: SML2010
DOI: 10.5281/zenodo.11557684
title: Chua et al. 2024 Kymographs of MeCP2 on DNA

description: Full kymographs of MeCP2 and RTT mutants on DNA. Associated with manuscript by Chua et al. 2024.
DOI: 10.6084/m9.figshare.27720183
title: Supplementary Material for: First-Line Lenvatinib Plus Pembrolizumab for Hepatocellular Carcinoma: Post Hoc Analysis of Japanese Patients From the Phase 3 LEAP-002 Trial

description: Introduction: The phase 3 LEAP-002 study (NCT03713593) of advanced hepatocellular carcinoma (HCC) suggested improved antitumor activity of lenvatinib plus pembrolizumab versus lenvatinib alone with manageable safety, although overall survival (OS) and progression-free survival (PFS) did not reach prespecified statistical significance. This post hoc analysis assessed efficacy and safety in Japanese patients.
Methods: Patients with advanced HCC without prior systemic treatment were randomly assigned 1:1 to receive 8 mg (body weight &lt;60 kg) or 12 mg (body weight ≥60 kg) oral lenvatinib once daily plus 200 mg intravenous pembrolizumab or placebo every 3 weeks for up to 35 cycles. Dual primary end points were OS and PFS per RECIST v1.1 by blinded independent central review (BICR). Secondary end points were objective response rate, disease control rate, duration of response, and time to progression per RECIST v1.1 by BICR and safety.
Results: Overall, 80 patients were enrolled in Japan (lenvatinib plus pembrolizumab, n = 39; lenvatinib plus placebo, n = 41). Median time from randomization to database cutoff (June 21, 2022) was 34.1 months (range, 26.9–39.6). Median OS was 31.4 months (95% CI: 21.2–not reached) for lenvatinib plus pembrolizumab and 21.4 months (95% CI: 14.4–25.4) for lenvatinib plus placebo (hazard ratio [HR] = 0.55 [95% CI: 0.31–0.96]). Median PFS for lenvatinib plus pembrolizumab was 10.4 months (95% CI: 6.2–18.5) and 6.5 months (95% CI: 6.0–8.3) for lenvatinib plus placebo (HR = 0.54 [95% CI: 0.32–0.90]). Grade 3 or 4 treatment-related adverse events occurred in 26 patients (67%) in the lenvatinib plus pembrolizumab group and 24 patients (59%) in the lenvatinib plus placebo group.
Conclusion: In Japanese patients enrolled in LEAP-002, findings were consistent with the global population where OS and PFS trended toward improvement; a similar safety profile was observed.
DOI: 10.15468/dl.69dndm
title: Occurrence Download

description: A dataset containing 1 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Camellia hekouensis C.J.Wang & G.S.Fan"
 ]
}

 The dataset includes 1 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0018162-241107131044228/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.2mqefb
title: Occurrence Download

description: A dataset containing 16 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 },
 "TaxonKey is one of (Aspidistra bogneri Tillich)"
 ]
}

 The dataset includes 16 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0018163-241107131044228/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.pkawbd
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 },
 "TaxonKey is one of (Aspidistra brachypetala C.R.Lin & B.Pan)"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0018165-241107131044228/datasets/export for details.
DOI: 10.15468/dl.2e6ahz
title: Occurrence Download

description: A dataset containing 55283 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is one of (Human Observation, Machine Observation, Observation)",
 "Country is Türkiye",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "IucnRedListCategory is one of (CR, EN, VU)"
 ]
}

 The dataset includes 55283 records from 44 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0018164-241107131044228/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.c6kj6n
title: Occurrence Download

description: A dataset containing 2 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 },
 "TaxonKey is one of (Aspidistra brachystyla Aver. & Tillich)"
 ]
}

 The dataset includes 2 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0018166-241107131044228/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.j9ea9b
title: Occurrence Download

description: A dataset containing 2 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 },
 "TaxonKey is one of (Aspidistra cadamensis N.S.Lý & Tillich)"
 ]
}

 The dataset includes 2 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0018168-241107131044228/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.bgp852
title: Occurrence Download

description: A dataset containing 52 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Camellia henryana Cohen-Stuart"
 ]
}

 The dataset includes 52 records from 11 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0018167-241107131044228/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.